0
What else can I help you with?
Is it ok to take a baby aspirin morning and one at night?
I don't think it matters. However, some people can get an upset stomach and have better luck taking them before bed. Sometimes, even when taken with food in the morning, they can still cause stomach discomfort. Good LucK! Have a beautiful and healthy baby! -- Some vitamins have been shown to have an energizing quality. For example, the vitamin B family plays a role in helping many biochemical reactions which speed up metabolism and increase circulation. This concept has been extended to use in "5 hour energy shots". However these don't wire you like caffinated drinks do, if anything they just facilitate metabolism in your body, so they shouldn't really affect how late you stay up. Many vitamins are also used in biosynthesis (anabolic functions) and function in regeneration of tissues. Thus if you are weight lifter and experience a lot of muscle soarness, it may be most beneficial to take vitamins in the evening. If you're tired on your 9-5 however, a multivitamin during the day might be the most useful.
[TargetMol Star Molecule] - ICG-001: Precision Modulation of Wnt/β-Catenin Signaling Unlocks New Ins?
. ICG-001 (T6113) was described as a Wnt signaling inhibitor that attenuates STAT3 signaling in multiple myeloma cells. In cell-based assays, ICG-001 reduced STAT3 phosphorylation in a concentration-dependent manner. It also decreased IL-6 expression and lowered levels of the Wnt target genes c-MYC and CCND1. Consistent with these biochemical changes, ICG-001 significantly reduced STAT3 reporter activity, demonstrating inhibition of STAT3-mediated transcriptional activity. In a xenograft mouse model using subcutaneous multiple myeloma tumors, combining ICG-001 with daratumumab produced marked anti-tumor effects. The combination strikingly delayed tumor growth compared to vehicle control and significantly slowed tumor growth relative to daratumumab alone. Endpoint analyses showed that tumors from the combination group were significantly smaller than those from vehicle or either monotherapy group. In tumor sections, immunohistochemistry confirmed increased CD38 expression upon ICG-001 administration, aligning with the observed enhancement of daratumumab efficacy. Together, these findings show that ICG-001 suppresses STAT3 signaling outputs, reduces IL-6 and key Wnt target gene expression, increases CD38 in tumors, and augments the anti-myeloma activity of daratumumab in vivo.[7] ■ 3. Conclusion ICG-001 acts by selectively disrupting the interaction between β-catenin and the coactivator CBP, sparing the β-catenin/p300 complex, thereby biasing transcriptional outputs of the Wnt/β-catenin pathway. Literature demonstrates that ICG-001 effectively inhibits β-catenin/TCF-mediated transcription, reducing apoptosis, inflammation, and tumor growth in various models including acute pancreatitis, gastric cancer, colitis, cardiotoxicity, and multiple myeloma. It also enhances cardioprotection and improves immunotherapy efficacy by modulating key signaling nodes such as STAT3 and mitochondrial dynamics. Future research may leverage ICG-001 to dissect epigenetic regulation of Wnt targets, optimize combination therapies in cancer treatment, and explore its potential in modulating apoptosis and regenerative processes. ■ 4. Q&A Q1: What is the specific molecular mechanism of ICG-001 in Wnt/β-catenin signaling? A1: ICG-001 selectively blocks the interaction between β-catenin and the coactivator CBP, sparing the β-catenin/p300 complex, which biases β-catenin toward p300-dependent transcription and reshapes the epigenetic and transcriptional landscape at Wnt target genes. Q2: How does ICG-001 affect disease models according to the literature? A2: ICG-001 reduces apoptosis and inflammatory cytokine secretion in pancreatic epithelial injury, shows high predicted binding affinity to β-catenin in gastric cancer docking studies, diminishes therapeutic efficacy in colitis models when co-administered, provides cardioprotection against doxorubicin-induced toxicity, suppresses cancer cell growth, and enhances anti-CD38 immunotherapy efficacy in multiple myeloma. Q3: What future research directions are suggested for ICG-001? A3: Future research may focus on using ICG-001 to dissect epigenetic coactivator choice in Wnt-responsive enhancers, investigate its role in apoptosis checkpoints under Wnt control, optimize its application in cancer combination therapies, and further explore its cardioprotective and immunomodulatory potentials. ■ 5. Reference [1] Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein-mediated transcription. Proc Natl Acad Sci U S A. 2004;101(34):12682-7. [2] MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26. [3] Jia X, Cui B, Liu X. Ductal epithelial MXD3 promotes disease progression in acute pancreatitis through Wnt/β-catenin-mediated inflammation and injury.. Frontiers in physiology. 2026;17():1785500. [4] Akhavan R, Foroughian M, Amerizadeh F. Integrative systems biology and drug repurposing reveal key regulatory hubs and a prognostic signature in gastric cancer.. Discover oncology. 2026;17(1):. [5] Xu T, Hou W, Yang S, Shao Y, Wang J, Han T, et al.. Danggui-Baishao herb pair protects against dextran sulfate sodium-induced colitis by modulating the Wnt/β-catenin pathway.. World journal of gastroenterology. 2026;32(5):113024. [6] Wu B, Chen J, Ma C, Kwok M, Chan V, Sung C, et al.. ICG-001 Provides Cardioprotection Against Doxorubicin-Induced Cardiotoxicity and Enhances Cancer Cytotoxicity.. JACC. Basic to translational science. 2026;11(2):101459. [7] Li H, Chen Y, Gregorova M, Yang T, Zhang X, Yu X, et al.. Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma.. Neoplasia (New York, N.Y.). 2025;70():101242.
